GHRP-2 vs GHRP-6 vs Ipamorelin: Selectivity Trade-offs in the Ghrelin Mimetic Class
Three of the most-discussed ghrelin receptor agonists for GH release. Same general mechanism, very different selectivity profiles. Here's how they differ on cortisol, prolactin, and appetite effects — and which fits which use case.
The 60-second version
GHRP-2, GHRP-6, and ipamorelin all activate the ghrelin receptor (GHSR-1a) to stimulate pituitary GH release. The differences are in selectivity. GHRP-2 produces strong GH release but elevates cortisol and prolactin. GHRP-6 produces moderate GH release with the distinctive feature of strong appetite stimulation (useful in cachexia, problematic for weight loss). Ipamorelin produces GH release with minimal cortisol/prolactin co-stimulation — the cleanest selectivity profile of the three. Modern community use has largely shifted to ipamorelin as the standard pairing for GHRH analogs because of the cleaner profile.
Key takeaways
- All three activate the ghrelin receptor (GHSR-1a) to stimulate pituitary GH release.
- GHRP-2: strong GH release but elevates cortisol and prolactin.
- GHRP-6: moderate GH release with strong appetite stimulation.
- Ipamorelin: GH release with minimal cortisol/prolactin/appetite effects — cleanest selectivity.
- Modern community use has shifted to ipamorelin as the standard GHRP partner for GHRH analogs.
- GHRP-6's appetite stimulation is useful for cachexia, problematic for weight loss.
- All three are research-grade; only macimorelin (oral ghrelin mimetic) has FDA diagnostic approval.
The shared mechanism
All three are ghrelin receptor (GHSR-1a) agonists. The receptor sits on anterior pituitary somatotrophs; activation triggers GH release. The receptor is distinct from the GHRH receptor that GHRH analogs (sermorelin, CJC-1295) target — which is why ghrelin mimetics are often paired with GHRH analogs for synergistic GH release through two parallel pathways.
Ghrelin itself is the natural ligand for this receptor. The synthetic ghrelin mimetics in this article all activate the same receptor but with different downstream effects on related pathways.
GHRP-2 profile
What it is: Synthetic hexapeptide, one of the original ghrelin mimetics from the GHRP class.
GH release magnitude: Strong — historically one of the more potent GHRP-class peptides.
Selectivity: Limited. GHRP-2 also elevates ACTH and cortisol, and increases prolactin levels.
Typical use: Historical research and earlier-era community use. Less commonly used today as more selective alternatives became available.
Limitations: Cortisol elevation undermines some of the benefits associated with GH release (anti-inflammatory effects, cortisol-related body composition issues). Prolactin elevation has potential implications for sexual function and fluid retention.
GHRP-6 profile
What it is: Synthetic hexapeptide, also from the original GHRP class.
GH release magnitude: Moderate — somewhat less than GHRP-2 at comparable doses.
Selectivity: Similar cortisol/prolactin issues as GHRP-2. Distinctive additional feature: strong appetite stimulation (one of the most-reported subjective effects).
Typical use: Niche applications where appetite stimulation is desired — cachexia, very lean athletes wanting to support mass gain, recovery from illness involving appetite loss. Problematic for weight loss contexts where appetite suppression is the goal.
Limitations: Same cortisol/prolactin issues plus the appetite-stimulating effect that limits use cases.
Ipamorelin profile
What it is: Synthetic pentapeptide developed specifically for receptor selectivity.
GH release magnitude: Moderate — similar to GHRP-6 at typical doses.
Selectivity: Substantially cleaner than GHRP-2 or GHRP-6. Minimal cortisol elevation, minimal prolactin elevation, no significant appetite stimulation.
Typical use: The community-standard ghrelin mimetic for most contexts. Paired with GHRH analogs (Modified GRF 1-29, CJC-1295) for synergistic GH release without the off-target effects of older GHRPs.
Limitations: Research-grade only (not FDA-approved for chronic use). Short half-life requires daily dosing. Effect magnitude is moderate — not the most potent option but the most selective.
Which fits which use case
General GH-secretagogue use (sleep, recovery, body composition): Ipamorelin. The cleaner selectivity profile makes it the standard choice. Pair with Modified GRF 1-29 for the canonical "CJC + Ipamorelin" stack.
Maximum GH release: Historical use of GHRP-2 produced higher peaks. Modern alternatives like macimorelin (FDA-approved oral) or MK-677 (oral, longer-acting) have largely replaced GHRP-2 for this purpose.
Cachexia or appetite stimulation needs: GHRP-6's appetite-stimulating side effect becomes the desired feature. Niche use case in oncology, geriatric recovery, or other low-appetite contexts. Anamorelin (FDA-approved for cancer cachexia in Japan) is the more developed option for this indication.
Patients with cortisol/prolactin sensitivity: Avoid GHRP-2 and GHRP-6. Ipamorelin's clean profile is essential.
The shift to ipamorelin
Modern peptide-research community use has largely converged on ipamorelin as the GHRP of choice. The reasons are clear from the selectivity comparison — getting the GH release without the cortisol elevation, prolactin elevation, and appetite stimulation gives ipamorelin a cleaner side-effect profile for most contexts.
GHRP-2 and GHRP-6 remain available in research-peptide channels but are increasingly relegated to specific niche use cases or historical reference. The "CJC + Ipamorelin" stack is the canonical modern protocol for endogenous GH/IGF-1 elevation; using GHRP-2 or GHRP-6 instead would be unusual today outside specific contexts.
Frequently asked questions
Why has ipamorelin replaced GHRP-2 and GHRP-6?
Cleaner selectivity. Ipamorelin produces GH release without elevating cortisol, prolactin, or appetite — making it more suitable for the general GH-secretagogue use cases that dominate community discussion.
When is GHRP-6 still useful?
Cases where appetite stimulation is desired — cachexia, low appetite during illness recovery, very lean athletes wanting mass gain. Niche but real use cases.
Are these safer than exogenous GH?
Different mechanism. They stimulate endogenous GH release rather than bypassing the pituitary. In principle, this preserves feedback regulation. In practice, sustained IGF-1 elevation produces similar long-term considerations.
Can I combine multiple GHRPs?
Generally not recommended. The ghrelin receptor saturates relatively early; adding multiple agonists doesn't proportionally increase GH release but does compound side effects.
References
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. https://pubmed.ncbi.nlm.nih.gov/9849822/
- Bowers CY. Growth hormone-releasing peptide (GHRP). Cell Mol Life Sci. 1998;54(12):1316-1329. https://pubmed.ncbi.nlm.nih.gov/9893707/
- Sigalos JT, Pastuszak AW. The safety and efficacy of growth hormone secretagogues. Sex Med Rev. 2018;6(1):45-53. https://pubmed.ncbi.nlm.nih.gov/28526632/
We update articles as new trials publish and the evidence base evolves. Last reviewed: May 2026.